Q

Quotient Technology

Optimizes promotions with proprietary data

Vice President – Translational Medicine

Full-Time
No salary listed
Expert
PhD, MD
Cambridge, UK
In Person
Biology & BiotechClinical Research Operations

About the job

Requirements
  • At least 4 years of clinical drug development experience within early-stage biotech, the pharmaceutical industry, and/or translational research settings.
  • MD, MD/PhD, or equivalent clinical training; meaningful experience in patient-facing roles is ideal.
  • Demonstrated success translating scientific ideas or drug targets into novel clinical development strategies and/or experimental medicine strategies.
  • Demonstrated experience driving disease-area and drug-discovery project strategy development across multiple disease and therapy areas.
  • Ability to quickly develop deep understanding of new therapeutic areas despite limited prior experience.
  • Ability to work in a scientifically rich, early discovery-stage setting and thrive in a fast-paced, dynamic environment.
Responsibilities
  • Provide expert clinical insight into disease-area strategy assessments, target selection, and translational biology planning across discovery projects.
  • Apply structured clinical reasoning across therapeutic areas to evaluate unmet need, current and future standards of care, patient, treatment, and diagnostic barriers, clinical feasibility, and early clinical signals.
  • Identify transformational medicine opportunities where the company’s platform can enable development of new medicines using approaches not possible with existing methods.
  • Gather and integrate scientific, clinical, commercial, and regulatory input to develop early target medicine profiles.
  • Adopt and test agentic artificial intelligence algorithms to support clinical indication ideation and clinical trial prediction for pipeline decision-making.
  • Develop novel clinical development strategies, detailed plans, study protocols, and associated documents across development phases, reflecting input from patients, evidence generation, regulators, payors, and pharmacovigilance.
  • Provide clinical expertise in regulatory interactions and documents, including briefing documents, presentations, and IND/CTA submissions.
  • Provide medical monitoring and oversee the safety of study participants in clinical trials.
  • Establish and nurture a network of external clinical experts and advisors to pressure-test hypotheses, support indication selection, and refine development strategies.
  • Serve as a clinical strategy partner in investor discussions and partnering conversations.
  • Integrate clinical insights across scientific, drug discovery, and corporate teams to support prioritization of disease areas, drug targets, medicine profiles, and early translational planning into clinical development strategies.
  • Assume clinical leadership of Phase 1/2 clinical trials, working with CROs and the internal clinical development team as the drug discovery pipeline expands.
Desired Qualifications
  • Meaningful time spent in patient-facing roles.

About the company

Quotient Technology helps brands run digital advertising and promotions across online and offline channels. It plans and executes integrated campaigns using proprietary data such as consumer spending patterns, location intelligence, and purchase intent to target audiences, optimize media spend, and measure results. Campaigns can reach people through social media, digital stores, and physical retail locations, with a focus on driving consumer engagement and improving ROI for advertisers. The company differentiates itself with exclusive data assets and a strong link between retailers, advertisers, and consumers, enabling precise targeting and omnichannel promotion management. The goal is to help businesses maximize the effectiveness and efficiency of their promotional efforts and their return on investment.

Company Size

201-500

Company Stage

IPO

Headquarters

Mountain View, California

Founded

1998

Get referred to Quotient Technology

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 2025 Neptune expanded DOOH into retail, adding new premium advertiser inventory.
  • August 2026 Neptune still ships product upgrades, signaling ongoing platform investment post-acquisition.
  • Checkout 51 receipt-scanning and in-store rights keep first-party shopper data flowing across channels.

What critics are saying

  • July 2026 Delaware settlement shows merger litigation still threatens management time and cash.
  • Charlesbank owns the combined company, limiting liquidity and forcing exit timing.
  • Retail media giants Amazon, Walmart, and Kroger can compress Neptune's margins and access.

What makes Quotient Technology unique

  • Neptune combines Quotient coupons, DOOH, and shopper data under one ownership since 2023.
  • Quotient’s retail network spans top grocers, drugstores, and Dollar General through Neptune.
  • Brand Safety for DOOH, launched August 2023, ties inventory to venue-level targeting.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Medical, dental, & vision coverage
  • Flexible PTO
  • Parental leave
  • 401k with company match
  • Wageworks commuter benefits program
  • Tuition reimbursement
  • Employee Stock Purchase Program
  • Organized recreation sports teams
  • Standing desks
  • Free snacks
  • Happy hours & team outings

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-2%
Consumer Goods Technology
Jan 11th, 2025
Quotient Acquires Elevaate to Boost Sponsored Search for CPGs

Quotient Technology announced it has acquired U.K.-based Elevaate, which has an in-market technology platform that drives e-commerce sales through sponsored search and product ads on retailers’ e-commerce properties and elsewhere on the web.

Business Wire
Nov 29th, 2024
 Quotient Signs Definitive Agreement to Acquire Ubimo

Quotient Signs Definitive Agreement to Acquire Ubimo - strengthening Quotient's targeted digital media platform

HomeVior
Oct 3rd, 2024
Furnishka raises Rs 27 crore led by India Quotient,, - Homevior

Bengaluru-based furniture retailer Furnishka has raised Rs 27 crore in a pre-series A funding round led by India Quotient, bringing the total raised by the company to Rs 45 crore.

TechObserver
Feb 28th, 2024
Reo.Dev raises $1.2 million in pre-seed funding led by India Quotient

Reo.Dev raises $1.2 million in pre-seed funding led by india Quotient.

CMO CRO
Oct 25th, 2023
AliveDx Nabs CE Marks for Connective Tissue Disease Tests

In December 2022, Quotient Limited announced it would file to delist its shares from the Nasdaq Global Market Exchange and lay off 100 employees.